Pregabalin (All indications)

Genital anomalies

id	Study   Auto Dudukina (Controls exposed to LTG) (Mixed indications), 2023Dudukina (Controls unexposed, NOS) (Mixed indications), 2023	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S15251 R62705	Dudukina (Controls exposed to LTG) (Mixed indications), 2023	Genital organs malformations	3 months or more before pregnancy or1st trimester	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: Yes	2.19 [1.06;4.53] excluded (control group)	-/2,332   -/7,005	-	2,332		ref
S15252 R62726	Dudukina (Controls unexposed, NOS) (Mixed indications), 2023	Genital organs malformations	3 months or more before pregnancy or1st trimester excluded	population based cohort retrospective	unexposed (general population or NOS)	Adjustment: Yes	1.61 [0.97;2.68] excluded (exposition period)	-/2,332   -/3,063,173	-	2,332		ref
					Total	0 studies	NaN [NaN;NaN]		0	0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis